Can a single dose of immunotherapy before surgery help fight recurrent brain tumors?

NCT ID NCT06069726

Recruiting now Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving one dose of the immunotherapy drug atezolizumab before surgery can help people with recurrent glioblastoma, a type of aggressive brain cancer. The main goal is to find biological markers (like tumor mutation burden) that predict who might benefit. About 80 adults with a first or second recurrence will receive the drug, then have their tumor removed, and researchers will track survival and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (a cancer immunotherapy drug)
What this could lead to: If successful, this could help identify which patients with recurrent glioblastoma might benefit from atezolizumab, potentially improving survival for a subset.
What could go wrong: This is a small, early-phase trial focused on biomarkers, not a direct test of a new treatment. The drug may not improve survival, and side effects like immune-related inflammation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA

Contacts and locations

Show contact details

Locations

Duke University
RECRUITING

Durham, North Carolina, 27705, United States
Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Saint Luke's Cancer Institute
ACTIVE_NOT_RECRUITING

Kansas City, Missouri, 64111, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.